Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer-Reference-Cited by-同舟云学术

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Published:2020-03 Issue:3 Volume:31 Page:377-386
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mosele F.,Stefanovska B.,Lusque A.,Tran Dien A.,Garberis I.,Droin N.,Le Tourneau C.,Sablin M.-P.,Lacroix L.,Enrico D.,Miran I.,Jovelet C.,Bièche I.,Soria J.-C.,Bertucci F.,Bonnefoi H.,Campone M.,Dalenc F.,Bachelot T.,Jacquet A.,Jimenez M.,André F.

Funder

AstraZeneca

Sanofi Pasteur

Novartis

GlaxoSmithKline Australia

Roche

Fondation ARC pour la Recherche sur le Cancer

Sanofi

Servier

Pfizer

Takeda Pharmaceutical Company

Amgen

Eli Lilly and Company

Breast Cancer Research Foundation

Association pour la Recherche sur le Cancer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. The phosphoinositide 3-kinase pathway;Cantley;Science,2002

2. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor;Brunet;Cell,1999

3. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu;Nat Rev Drug Discov,2009

4. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer;Forbes;Nucleic Acids Res,2011

5. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma;Saal;Cancer Res,2005

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer;Cells;2024-09-10

2. Circulating Tumor DNA and Survival in Metastatic Breast Cancer;JAMA Network Open;2024-09-05

3. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer;Cancer Medicine;2024-09

4. Identification of breast cancer-associated PIK3CA H1047R mutation in blood circulation using an asymmetric PCR assay;PLOS ONE;2024-08-28

5. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10